Telix Pharmaceuticals (ASX:TLX) said Thursday that its fibroblast-activation-protein-targeting therapy candidate, TLX400, was published in Thyroid, the official journal of the American Thyroid Association, providing further validation of the safety profile and potential efficacy of TLX400.

TLX400 showed an "encouraging" safety profile and efficacy in aggressive, radioiodine-resistant thyroid cancer, according to a statement. It has been in-licensed by Telix as part of a portfolio of next-generation therapeutic and diagnostic radiopharmaceutical candidates.

"In the cohort of patients with reported efficacy, the treatment demonstrated median overall survival and progression-free survival durations of 32 months and 29 months, with a promising 50% partial response rate," Sanjana Ballal, investigator and lead author noted.

However, potential risks, including significant side effects, require careful management, particularly in patients with comorbidities such as cardiac issues, hypertension, stroke, and kidney dysfunction, who may not be optimal candidates for tyrosine kinase inhibitor therapy, Telix said.

The company's shares slipped almost 1% in recent Thursday trade.